Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

Nov. 22, 2023

Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.